Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis

Abstract Background and Aims The availability of biological agents for inflammatory bowel disease has increased over the past years. In this systematic review and meta‐analysis, we aimed to explore time trends in clinical response and clinical remission rates in Crohn's disease (CD) patients treated with biologics while discussing the need for new strategies. Methods MEDLINE, Cochrane, and ISI Web of Science databases were searched for randomized placebo‐controlled trials with biological agents in moderate‐to‐severe CD patients. Sub‐group and meta‐regression analyses compared treatment and placebo by calculating the pooled odds ratios of clinical remission and clinical response, across time categories and publication year. We also estimated the proportion of patients achieving clinical remission and clinical response by comparing both groups according to the publication year. Results Twenty‐five trials were included in the systematic review, which enrolled 8879 patients between 1997 and 2022. The clinical remission and clinical response odds, in induction and maintenance, have been constant over time, as no statistically significant differences were found between time categories (interaction p‐values: clinical remission [induction, p = 0.19; maintenance, p = 0.24]; clinical response [induction, p = 0.43; maintenance, p = 0.59]). In meta‐regression analyses, publication year did not influence these outcomes (clinical remission [induction, OR 1.01{95% CI 0.97–1.05}, p = 0.72; clinical response [induction, OR 1.01{95% CI 0.97–1.04]; p = 0.63; maintenance, OR 1.03{95% CI 0.98–1.07}; p = 0.21]), with the exception of clinical remission in maintenance studies, which presented a decreased effect (odds ratio 0.97{95% CI 0.94–1.00}, p = 0.03]). Conclusions Our review highlights that the odds of clinical outcomes in CD patients receiving biological treatment relative to placebo have been stable in the last decades.

[1]  D. Rubin,et al.  Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. , 2022, Gastroenterology.

[2]  E. Loftus,et al.  Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease , 2022, Crohn's & colitis 360.

[3]  P. Higgins,et al.  Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. , 2021, Gastroenterology.

[4]  G. Kaplan,et al.  Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. , 2021, Gastroenterology.

[5]  S. Vermeire,et al.  Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial , 2021, Journal of Crohn's & colitis.

[6]  Harminder Singh,et al.  AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.

[7]  S. Mehandru,et al.  Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. , 2021, Gastroenterology.

[8]  Jana G Hashash,et al.  Positioning biologics in the management of moderate to severe Crohn's disease , 2021, Current opinion in gastroenterology.

[9]  T. Matsui,et al.  Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses , 2019, Journal of Gastroenterology.

[10]  J. Stapelbroek,et al.  UEG Week 2019 Oral Presentations , 2019, United European gastroenterology journal.

[11]  S. McCartney,et al.  Biologic therapies for Crohn’s disease: optimising the old and maximising the new , 2019, F1000Research.

[12]  M. Oda,et al.  UEG Week 2017 Oral Presentations , 2017, United European Gastroenterology Journal.

[13]  K. Papadakis,et al.  Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics , 2017, Gut and liver.

[14]  A. Kaser,et al.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study , 2017, The Lancet.

[15]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[16]  P. Poitras,et al.  Biologics in inflammatory bowel disease: what are the data? , 2015, United European gastroenterology journal.

[17]  L. Peyrin-Biroulet,et al.  Biologic agents for IBD: practical insights , 2015, Nature Reviews Gastroenterology &Hepatology.

[18]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[19]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[20]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[21]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[22]  T. Hibi,et al.  Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[23]  P. Rutgeerts,et al.  Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[25]  R. Bloomfeld,et al.  An analysis of the placebo effect in Crohn’s disease over time , 2010, Alimentary pharmacology & therapeutics.

[26]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[27]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[28]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[29]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[30]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[31]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[32]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[33]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[34]  A. Innes,et al.  Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study , 2004, Alimentary pharmacology & therapeutics.

[35]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[36]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[37]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[38]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[39]  G. Tytgat,et al.  Tumour-necrosis-factor antibody treatment in Crohn's disease , 1993, The Lancet.